MYORISAN SIDE EFFECTS
- Generic Name: isotretinoin capsules
- Brand Name: Myorisan
- Drug Class: Acne Agents, Systemic
SIDE EFFECTS
Clinical Trials And Postmarketing Surveillance
The adverse reactions listed below reflect the experience from investigational studies of Myorisan, and the postmarketing experience. The relationship of some of these events to Myorisan therapy is unknown. Many of the side effects and adverse reactions seen in patients receiving Myorisan are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, eg, of the lips, nasal passage, and eyes).
Dose Relationship
Cheilitis and hypertriglyceridemia are usually dose related. Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy.
Body as a Whole
allergic reactions, including vasculitis, systemic hypersensitivity, edema, fatigue, lymphadenopathy, weight loss
Cardiovascular
palpitation, tachycardia, vascular thrombotic disease, stroke
Endocrine/Metabolic
hypertriglyceridemia, alterations in blood sugar levels.
Gastrointestinal
inflammatory bowel disease, hepatitis, pancreatitis, bleeding and inflammation of the gums, colitis, esophagitis/esophageal ulceration, ileitis, nausea, other nonspecific gastrointestinal symptoms.
Hematologic
allergic reactions, anemia, thrombocytopenia, neutropenia, rare reports of agranulocytosis
Musculoskeletal
skeletal hyperostosis, calcification of tendons and ligaments, premature epiphyseal closure, decreases in bone mineral density musculoskeletal symptoms (sometimes severe) including back pain, myalgia, and arthralgia, transient pain in the chest, arthritis, tendonitis, other types of bone abnormalities, elevations of CPK/rare reports of rhabdomyolysis.
Neurological
pseudotumor cerebri , dizziness, drowsiness, headache, insomnia, lethargy, malaise, nervousness, paresthesias, seizures, stroke, syncope, weakness.
Psychiatric
suicidal ideation, suicide attempts, suicide, depression, psychosis, aggression, violent behaviors, emotional instability.
Of the patients reporting depression, some reported that the depression subsided with discontinuation of therapy and recurred with reinstitution of therapy.
Reproductive System
Abnormal menses.
Respiratory
bronchospasms (with or without a history of asthma), respiratory infection, voice alteration
Skin and Appendages
acne fulminans, alopecia (which in some cases persists), bruising, cheilitis (dry lips), dry mouth, dry nose, dry skin, epistaxis, eruptive xanthomas,7 erythema multiforme, flushing, fragility of skin, hair abnormalities, hirsutism, hyperpigmentation and hypopigmentation, infections (including disseminated herpes simplex), nail dystrophy, paronychia, peeling of palms and soles, photoallergic /photosensitizing reactions, pruritus, pyogenic granuloma, rash (including facial erythema, seborrhea, and eczema), Stevens-Johnson syndrome, sunburn susceptibility increased, sweating, toxic epidermal necrolysis, urticaria, vasculitis (including Wegener’s granulomatosis, abnormal wound healing (delayed healing or exuberant granulation tissue with crusting
Special Senses
Hearing
hearing impairment, tinnitus.
Vision
corneal opacities , decreased night vision which may persist , cataracts, color vision disorder, conjunctivitis, dry eyes, eyelid inflammation, keratitis, optic neuritis, photophobia, visual disturbances
Urinary System
glomerulonephritis, nonspecific urogenital findings
Laboratory
Elevation of plasma triglycerides, decrease in serum high-density lipoprotein (HDL) levels, elevations of serum cholesterol during treatment
Increased alkaline phosphatase, SGOT (AST), SGPT (ALT), GGTP or LDH
Elevation of fasting blood sugar, elevations of CPK, hyperuricemia
Decreases in red blood cell parameters, decreases in white blood cell counts (including severe neutropenia and rare reports of agranulocytosis; , elevated sedimentation rates, elevated platelet counts, thrombocytopenia
White cells in the urine, proteinuria, microscopic or gross hematuria
REFERENCES
7. Dicken CH, Connolly SM. Eruptive xanthomas associated with isotretinoin (13-cis-retinoic acid). Arch Dermatol 116:951-952, 1980.
SRC: NLM .